[177lu]lu-dota-eb-rgd2
Recurrent High-Grade Gliomas
Beijing Tiantan HospitalradiopharmaceuticalEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
108 Active assets in the Recurrent High-Grade Gliomas cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Kailin Yang, MD, PhD | Phase 2 | BB |
Marizomib Aadi Bioscience, Inc. | Phase 2 | BB |
Valaciclovir Trogenix ltd | Phase 2 | BB |
Valproic Acid Virginia Commonwealth University | Phase 2 | BB |
DISODIUM 4-((TERT-BUTYLIMINO)METHYL)BENZENE-1,3-DISULFONATE N-OXIDE Oblato, Inc. | Phase 2 | BB |
View all 50 →
Same molecule, other indications
[177lu]lu-dota-eb-rgd2 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →